
FibroGen, Inc: A global, research-based pharmaceutical company in San Francisco, innovating treatments for unmet medical needs.
FibroGen, Inc. is a research-based pharmaceutical company headquartered in San Francisco, focused on discovering, developing, and commercializing novel therapeutic agents to address serious unmet medical needs. The company has a global approach, with a notable presence in China, and is dedicated to advancing therapies at the frontiers of cancer biology and other life-threatening diseases. FibroGen's pipeline includes groundbreaking products aimed at significantly improving patient outcomes.
FibroGen has achieved significant milestones in its mission to innovate within the pharmaceutical industry. The company has developed a robust clinical trial program and has introduced world-class innovations in China. By focusing on responsible development and commercialization of its therapies, FibroGen has made a substantial impact on the global healthcare landscape, contributing to the advancement of treatments for serious conditions.

MacroGenics
macrogenics.com

BridgeBio Pharma
bridgebio.com

Genentech
gene.com

Pliant Therapeutics
pliantrx.com

Blade Therapeutics

SphynKx Therapeutics
Bristol Myers Squibb
bms.com

Goldfinch Bio

Ferring
ferring.com

Angion
elicio.com

BeOne Medicines
beigene.com

Karyopharm Therapeutics
karyopharm.com

Harmony Biosciences

Kronos Bio

Athenex
Companies similar to Kyntra Bio include MacroGenics, BridgeBio Pharma, Genentech and Pliant Therapeutics.
Kyntra Bio was founded in 1993.
Kyntra Bio's headquarters is located in San Francisco, CA, US.
Kyntra Bio's most recent funding round was for $62M (USD) in July 2016.
As of Jul 8, 2016, Kyntra Bio has raised a total of $188M (USD).
Kyntra Bio has 592 employees as of Feb 6, 2024.